Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma

Antiangiogenic therapy resistance occurs frequently in patients with metastatic renal cell carcinoma (RCC). The purpose of this study was to understand the mechanism of resistance to sunitinib, an antiangiogenic small molecule, and to exploit this mechanism therapeutically. We hypothesized that suni...

詳細記述

保存先:
書誌詳細
出版年:Oncogene
主要な著者: Zhou, Lijun, Liu, Xian-De, Sun, Mianen, Zhang, Xuesong, German, Peter, Bai, Shanshan, Ding, Zhiyong, Tannir, Nizar, Wood, Christopher G, Matin, Surena F, Karam, Jose A, Tamboli, Pheroze, Sircar, Kanishka, Rao, Priya, Rankin, Erinn B., Laird, Douglas A, Hoang, Anh G, Walker, Cheryl L, Giaccia, Amato J, Jonasch, Eric
フォーマット: Artigo
言語:Inglês
出版事項: 2015
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4791213/
https://ncbi.nlm.nih.gov/pubmed/26364599
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2015.343
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料